Drug intelligence / Profile preview

NefTat

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NefTat is a biological vaccine candidate initially developed by the National Institute of Allergy & Infectious Diseases (NIAID) for HIV treatment. It appears to be composed of HIV proteins Nef and Tat, designed to stimulate immune responses against HIV infection. The vaccine has been studied both alone and in combination with other HIV vaccine components such as gp120w61d and formulated with adjuvants like AS02A to enhance immunogenicity.

Other names: Nef-Tat

Targets

Tat (HIV-1 Tat)Nef (HIV-1 Nef)

Beyond the preview

Go deeper on NefTat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NefTat.

Explore the full profile